Co-Authors
This is a "connection" page, showing publications co-authored by Chih-Yi Liao and Xavier Keutgen.
Connection Strength
1.398
-
Surgery enhances the effectiveness of peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumors. Surgery. 2024 Oct 11.
Score: 0.248
-
MEN1/DAXX/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy. Endocr Relat Cancer. 2024 Nov 01; 31(11).
Score: 0.248
-
Peptide Receptor Radionuclide Therapy versus Capecitabine/Temozolomide for the Treatment of Metastatic Pancreatic Neuroendocrine Tumors. Cancers (Basel). 2024 Aug 28; 16(17).
Score: 0.246
-
Light It Up! The Use of DOTATATE in Diagnosis and Treatment of Neuroendocrine Neoplasms. Surg Pathol Clin. 2023 Mar; 16(1):151-161.
Score: 0.218
-
Loss of MEN1 function impairs DNA repair capability of pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2022 03 21; 29(4):225-239.
Score: 0.208
-
Response rates in metastatic neuroendocrine tumors receiving peptide receptor radionuclide therapy and implications for future treatment strategies. Surgery. 2021 01; 169(1):162-167.
Score: 0.183
-
Deep learning prediction of BRAF-RAS gene expression signature identifies noninvasive follicular thyroid neoplasms with papillary-like nuclear features. Mod Pathol. 2021 05; 34(5):862-874.
Score: 0.048